Bringing the fundamentals into focus…
Back to ADMA Biologics, Inc.
How ADMA Biologics, Inc. stacks up
ADMA · against 365 other Healthcare companies of similar size
Valuation
81/ 100
Near the top of its peers.
Ranked #73 of 366 · scores higher than 78% of peers
Bars: peers in each 10-point band of the valuation score52 peers with a valuation score of 80–89, including ADMA · Click a bar to see the companies
Why valuation scores 81?
Weighted metrics compared with all Healthcare companies.Mainly thanks to its earnings yield, free cash flow yield and EBITDA yield, which are stronger than most Healthcare peers.
- more operating profit (EBITDA) for the company's total value: stronger than 76% of peers. EBITDA yield: 9.1% vs peer median 4.0%
- more free cash flow for the price paid: stronger than 77% of peers. Free cash flow yield: 4.7% vs peer median 0.0%
- higher earnings for the price paid: stronger than 85% of peers. Earnings yield: 6.8% vs peer median 1.5%
Metric by metric
Position: dot = ADMA, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | ADMA | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 356 reported | 6.3% | 2.1% | 82% | 30% | |
| EBITDA yieldHigher is better · 364 reported | 8.8% | 4.5% | 76% | 50% | |
| Free cash flow yieldHigher is better · 181 reported | 4.7% | -0.2% | 74% | 20% | |
| Book yieldHigher is better · 356 reported | 16.3% | 32.7% | 23% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around ADMAScores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score